Effectiveness of the application of Heberprot-P in the elderly with diabetic foot ulcers

Authors

Keywords:

DIABETIC FOOT, DIABETES MELLITUS, EPIDERMAL GROWTH FACTOR, AMPUTATION, PERIPHERAL VASCULAR DISEASES.

Abstract

Introduction: Heberprot-P is a treatment that has proved to be effective in the treatment of diabetic foot ulcers.

Objective: to characterize the evolution of the elderly with diabetic foot ulcers treated with Heberprot-P in Pinar de Rio.

Methods: an observational, descriptive, longitudinal and retrospective study was carried out in the elderly treated with Heberprot-P for presenting diabetic foot ulcers in the period 2017-2020. The target group comprised 140 patients, and all of them were studied. Descriptive statistics was applied using absolute and relative percentage frequencies.

Results: it was found a predominance of female patients (55,72 %), of the age group between 60 and 69 years (60 %) and with neuro-infectious diabetic foot (67,14 %). Ulcer infection was detected in 10 patients (7,1 %) and was associated with lack of granulation (p=0,003; OR=16.11; 95%CI=1.90-726.03). Amputation was required in 13,6 % of patients. An association was found between non-granulation and the requirement for amputation (p<0,05); 37,9 % of the patients presented some adverse response to the administration of Heberprot-P.

Conclusions: the treatment with Heberprot-P showed encouraging results. The presence of adverse events was relatively high, being these of low repercussions,  which ratifies Heberprot-P as an effective and safe treatment to accelerate the healing of diabetic foot ulcers and prevent the need for amputation.

Downloads

Download data is not yet available.

Author Biographies

Ana Lidia Hernández Rojas, Hospital Universitario Clínico Quirúrgico "Abel Santamaría Cuadrado"

Dra.. Ana Lidia Hernández Rojas.
Especialista de 1er grado en Angiología y Cirugía Vascular.
HUCQ.: "Abel Santamaría Cuadrado"
Pinar del Río, Cuba.

Aida Rosa Hernández Díaz, Universidad de Ciencias Médicas de Pinar del Río .Hospital General Docente “Abel Santamaría Cuadrado”. Pinar del Río, Cuba.

Especilaista 1er grado en Angiología

Sissy Del Campo Martínez, Policlínico Augusto Turcios Lima

Especialista 1er Grado en MGI. Instructor

Yoleiny de la Caridad Lescalle Ortiz, Policlinico Pedro Borras Astorga

Especilista de 1er grado en MGI, Instructor

References

1. Federación Internacional de Diabetes (FID). Diabetes Atlas de la FID [Internet]. 8 Ed. FID; 2017 [Citado 23/01/2020]. Disponible en: Disponible en: http://fmdiabetes.org/wp-content/uploads/2018/03/IDF-2017.pdf

2. Centro Nacional de Información de Ciencias Médicas. Biblioteca Médica Nacional. Diabetes. Estadísticas Mundiales. Facto gráfico salud. Cuba: CNICM; 2019 Jun [Citado 15/07/2019]; 5(6). Disponible en: https://files.sld.cu/bmn/files/2019/06/factografico-de-salud-junio-2019.pdf

3. Organización Mundial de la Salud. Diabetes. Ginebra: OMS; 2016 [Citado 10/03/2019]. Disponible en: Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/diabetes

4. Velázquez Chacón W. El pie diabético: usted puede prevenirlo. En: ¿Qué es el pie diabético? Definición. Santiago de Cuba: Editorial Oriente;2014p.87-89.

5. Colectivo de autores. Implementación de la atención integral al paciente con úlcera del Pie Diabético con el uso del Heberprot-P en Cuba. En: Colectivo de autores. Infiltración del Heberprot-P: un tratamiento eficaz para la úlcera del pie diabético. La Habana: Elfos Scientiae ;2014. p.41-43.

6. Cuba. Ministerio de Salud Pública. Anuario Estadístico de Salud 2019 [Internet]. La Habana: Minsap;2020. [Citado 13/03/2020]. Disponible en: Disponible en: http://www.onei.gob.cu/node/15006

7. Romero Gamboa MC, Sández López M. Evolución del pie diabético en los grados 4 y 5 de la clasificación de Wagner. Rev Cubana Angiol Cir Vasc [Internet]. 2017 [citado 13/03/2020]; 18(1):71-81. Disponible en: Disponible en: http://scielo.sld.cu/pdf/ang/v18n1/ang07117.pdf

8. Falcón Fariñas IN, Escalante Padró O, Nordelo Valdivia A. Evaluación social del tratamiento con el Heberprot-p ® en la asistencia primaria de salud. Rev Cubana Angiol Cir Vasc [Internet]. 2018 [citado 13/03/2020]; 19(1):53-64. Disponible en: Disponible en: http://scielo.sld.cu/pdf/ang/v19n1/ang07118.pdf

9. Catalá Sardiñas E, Albanes García A, Sardiñas Díaz I, García Cabrera Y, Pinillos Viera PA. Características de los diabéticos tratados con Heberprot-P® en el municipio de Colón. Rev Cubana Angiol Cir Vasc [Internet]. 2018 [citado 19/03/2019]; 19(1):28-35. Disponible en: Disponible en: http://scielo.sld.cu/pdf/ang/v19n1/ang04118.pdf

10. Rodríguez Rodríguez Y, Martínez Gálvez I. Características del paciente con pie diabético no isquémico tratado con Heberprot-P®. Rev Cubana Angiol Cir Vasc [Internet]. 2018 [citado 13/03/2019]; 19(1): 36-45. Disponible en: Disponible en: http://scielo.sld.cu/pdf/ang/v19n1/ang05118.pdf

11. Escalante Gutiérrez D, Lecca García L, Gamarra Sánchez J, Gutiérrez Escalante G. Amputación del miembro inferior por pie diabético en hospitales de la costa norte peruana 1990 - 2000: características clínico-epidemiológicas. Rev peru med exp salud Publica. [Revista en Internet] 2003 [Citado 05/09/2009]; 20(3). Disponible en: http://www.scielo.org.pe/pdf/rins/v20n3/a05v20n3.pdf.

12. Escobar Amarales Y, Torres Romo UR, Escalante Padrón O, Fernández Franch N, Ibarra Viena l, Miranda Rodríguez E. El Heberprot-P(r) en el tratamiento de úlceras del pie diabético. AMC. 2014 [Citado 08/09/2019]; 18(3):297-308. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552014000300005&lng=es

13. Verdaguer Pérez L, Muguercia Silva JL, Ayala Lafargue D, Bertrán Bahades J, Estrada Ladoy L. Experiencias en el tratamiento con Heberprot-P(r) en pacientes con pie diabético. Medisan. 2017 [Citado 09/05/2019]; 21(8):993-9. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192017000800005&lng=es

14. Hernández Cañete CM, Jácome Ruiz R, Iturralde Mc Farlen L, Sánchez Montiel ME. Resultados y reacciones adversas en pacientes tratados con Heberprot-P(r) en la comunidad. Rev Cubana Angiol Cir Vasc. 2017 Jun [Citado 23/12/2019]; 18(1):35-42. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1682-00372017000100004

Downloads

Published

2021-04-13

How to Cite

1.
Hernández Rojas AL, Hernández Díaz AR, Del Campo Martínez S, Lescalle Ortiz Y de la C. Effectiveness of the application of Heberprot-P in the elderly with diabetic foot ulcers. Rev Ciencias Médicas [Internet]. 2021 Apr. 13 [cited 2025 Sep. 18];25(2):e4975. Available from: https://revcmpinar.sld.cu/index.php/publicaciones/article/view/4975

Issue

Vol. 25 No. 2 (2021)

Section

ORIGINAL ARTICLES

License

Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.

Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/